Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 1/20 | 0.46 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | GPR18 | Q14330 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 4/20 | 0.36 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.35 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.35 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6702588 | 0.93 | MMP13 (0.39) | MMP13SLC22A8PTGS1PTGS2GPR18 | |
| SCHEMBL6698004 | 0.90 | MAPT (0.41) | MMP13SLC22A8MAPT | |
| SCHEMBL6704878 | 0.86 | MMP13 (0.48) | MMP13SLC22A8PTGS1PTGS2GPR18 | |
| SCHEMBL6703297 | 0.82 | MMP13 (0.42) | MMP13SLC22A8GPR18MAPTGRIN1 | |
| SCHEMBL6700340 | 0.80 | MMP13 (0.44) | MMP13SLC22A8GPR18MAPTADORA3 | |
| SCHEMBL6392558 | 0.79 | MMP13 (0.72) | MMP13SLC22A8PTGS1PTGS2 | |
| SCHEMBL6681942 | 0.78 | MMP13 (0.46) | MMP13SLC22A8PTGS1PTGS2GPR18 | |
| SCHEMBL6843728 | 0.78 | MMP13 (0.48) | MMP13SLC22A8PTGS1PTGS2GPR18 | |
| SCHEMBL6698891 | 0.78 | PTGS1 (0.41) | MMP13SLC22A8PTGS1PTGS2GPR18 | |
| SCHEMBL6700333 | 0.77 | S1PR3 (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040038994-A1 | Pyrimidine fused bicyclic metalloproteinase inhibitors | WILSON MICHAEL WILLIAM (US) | 2004-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038994-A1 | Pyrimidine fused bicyclic metalloproteinase inhibitors | MMP9, MMP1, MMP2 | MMP13 13/4885SLC22A8 2959/4885PTGS1 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.